NIH Panels Meet Behind Closed Doors on Research Grants
Published Date: 6/17/2026
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important grant applications. These meetings protect private info and trade secrets while helping fund research on mice, drug development, and primate centers. Scientists and research groups applying for grants should watch for these dates as they impact funding decisions.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
NIH grant reviews set for July 14–16, 2026
The NIH Center for Scientific Review will hold closed meetings on July 14–16, 2026 to review and evaluate grant applications for multiple programs, including RFA-OD-25-012 (Mutant Mouse Resource), infrastructure for drug development/medication repurposing for SUDs, National Primate Research Centers (P51), Maximizing Investigators' Research Award, and several others. If you or your research group applied to these programs, your application will be evaluated on those dates and those reviews drive funding decisions.
Reviews closed to protect trade secrets and privacy
The meetings will be closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, commercial property such as patentable material, and personal information about individuals associated with applications. This means applicants' proprietary or private details discussed during review are not open for public inspection.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-19431, Government-Owned Inventions; Availability for Licensing
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
2026-19303, Submission for OMB review; 30-Day Comment Request; the Impact and Costs of Promoting Objectivity in Research 42 CFR Part 50 Subpart F and Responsible Prospective Contractors 45 CFR Part 94 (Office of the Director)
The National Institutes of Health (NIH) is asking for your thoughts on how they collect info to keep research honest and fair. This affects researchers and contractors who work with NIH, aiming to make sure everything stays clear and trustworthy. You’ve got until October 22, 2026, to share your comments—no cost changes, just a check-in to keep things running smoothly!
2026-19155, Proposed Collection; 60-Day Comment Request; PHS Applications and Pre-Award Reporting Requirements (OD)
The NIH is updating how researchers submit their Public Health Service applications and reports before awards, starting May 25, 2026. This change aims to make data management clearer and easier, affecting anyone applying for NIH funding. They want your feedback by November 17, 2026, to help improve the process without adding extra hassle or costs.
2026-19156, Proposed Collection; 60-Day Comment Request; Post-Award Reporting Requirements Including Research Performance Progress Report (OD)
The National Institutes of Health (NIH) wants your thoughts on updating how researchers report their progress after getting awards. This affects anyone who receives NIH funding and aims to make reporting clearer and less of a hassle. Comments are due by November 17, 2026, so don’t miss your chance to weigh in!
2026-18937, Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form (Office of the Director/Office of Intramural Research)
The NIH is rolling out a new online form to make reporting research cheating easier and fairer. Anyone involved with NIH research can use this form to report problems like lying or copying, even anonymously. They want your feedback by November 16, 2026, to make sure the form works well without causing extra hassle.
2026-18877, Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of HPV 16 E6-Expressing Cancers
The National Cancer Institute plans to give MedGene Therapeutics an exclusive license to develop and sell special engineered cell treatments for cancers caused by HPV 16 E6. This means MedGene will have the sole right to use these inventions, potentially speeding up new cancer therapies. If you want to comment or apply for a license, you must do so by September 30, 2026.
Previous / Next Documents
Previous: 2026-12115, Notice of Determinations; Culturally Significant Objects Being Imported for Exhibition-Determinations: “Krasner and Pollock: Past Continuous” Exhibition
The U.S. government has approved the temporary import of important artworks for the “Krasner and Pollock: Past Continuous” exhibition at The Metropolitan Museum of Art in New York. This means these culturally valuable pieces can be shown in the U.S. because it benefits the public and the nation. Art lovers and museum visitors can enjoy this special exhibit soon, with no extra costs or delays announced.
Next: 2026-12119, Foreign-Trade Zone (FTZ) 41, Notification of Proposed Production Activity; Dedicated Computing; (Computer Systems); Waukesha, Wisconsin
Dedicated Computing in Waukesha, Wisconsin wants to start making special industrial computer systems and parts inside Foreign-Trade Zone 41. This means they can bring in certain foreign materials duty-free and save money while building cool tech products. The government got their proposal on June 8, 2026, and if approved, it could speed up production and cut costs for the company.